Virtual Library

Start Your Search

Igor Andrasina



Author of

  • +

    EP1.04 - Immuno-oncology (ID 194)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Immuno-oncology
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.04-19 - First Experience with Atezolizumab in Slovakia (Now Available) (ID 2869)

      08:00 - 18:00  |  Author(s): Igor Andrasina

      • Abstract
      • Slides

      Background

      New immunotherapeutics, PD-1 and PD-L1 checkpoint signalling inhibitors, have improved the prospects of patients with advanced non-small cell lung cancer (NSCLC). The purpose of this study was to assess the first results achieved with the PD-L1 inhibitor atezolizumab in the treatment of advanced NSCLC in Slovakia.

      Method

      The data of patients who entered the pre-approval access programme with atezolizumab between June 2017 and September 2017 were reviewed in the retrospective multicentre study. Data regarding patients were obtained from the databases of participating institutions and patient files. Statistical analyses were performed using MedCalc®software. PFS and OS were estimated using the Kaplan–Meier method, based on the data available by the end of March 2019.

      Result

      Altogether 22 patients were included. Characteristics of patients: median age, years (range): 63 (41 - 85), female/male: 3/19, ECOG PS: 0, 1, 2, 3 in 6, 11, 3, 2 patients, respectively. Histology: 8 squamous, 14 non-squamous. Patients with locally advanced disease: 1, with metastatic disease: 21. Treatment lines before atezolizumab: median: 2 (range: 1 - 3). Median PFS: 5 months (95%CI: 4 - 10). Median OS: 11 months (95%CI: 8 – 20). Complete/partial response: 1/4 patients. Median PFS in patients with complete or partial response was not achieved but will be over 19 months (range: 13 – 21+). Two patients only had to discontinue atezolizumab due to toxicities (pneumonitis and hepatitis).

      Conclusion

      Results from our retrospective study are similar to those seen in the phase III trial OAK, excepting PFS. However, the different CT scanning schedules for the response evaluations and follow up in the different participating institutions could influence numerically better PFS seen in our patients.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    EP1.14 - Targeted Therapy (ID 204)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Targeted Therapy
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.14-34 - Advanced NSCLC Treated with Gefitinib or Erlotinib for Five Years or Longer - Updated Data from the Retrospective Slovakian Study (Now Available) (ID 3009)

      08:00 - 18:00  |  Author(s): Igor Andrasina

      • Abstract
      • Slides

      Background

      Median PFS in the key phase III trials with gefitinib or erlotinib for advanced NSCLC with EGFR sensitizing mutations was less than 12 months. There are only a few data about the treatment results and toxicity of long-term treatment lasting 5 years or over. Purpose of this study was to find patients treated with either gefitinib or erlotinib for at least 5 years and to evaluate the treatment results in this group of patients.

      Method

      Retrospective multicentre study, approved by the Ethics Committee of the Specialised Hospital of St Zoerardus Zobor, Nitra. All thoracic oncology centres in Slovakia were involved. For this update also the other hospitals and oncology outpatient departments were asked to participate. Data regarding patients were obtained from the databases of participating institutions and patient files. Descriptive statistics was used for the data analysis.

      Result

      At the IASLC WCLC 2018 we presented data about seven patients included in the study. Here we present the data about another two patients, and updated data about the previously found seven patients. Characteristics of patients and the treatment results are summarised in the Table. Median PFS in this exceptional group was not reached, but it will be over 80 months. There was only one patient with the decreased dose of erlotinib (from 150 to 100 mg QD) due to skin toxicities. All the other patients had the common and manageable grade I – II toxicities only, and there were no unexpected drug-related AEs.

      Table: Patients characteristics and treatment results

      Gender
      (M/W)
      Age
      (yrs)
      Smoking
      status
      PS Histology,
      Cytology
      NSCLC
      stage
      EGFR
      mutation
      Treatment line/TKI Response PFS
      (mo)
      W 72 Ex 2 AC IV Del 19* 1st/gefitinib SD 67
      W 53 Smoker 1 AC IV NK 1st/erlotinib SD 112+
      W 58 Never 1 AC/SQ IIIB NK 2nd/erlotinib PR 94+
      W 69 Never 1 AC IV NK 2nd erlotinib SD 87+
      W 72 Never 1 AC IV Del 19 2nd erlotinib PR 75+
      W 59 Never 1 AC IV L858R 1st/erlotinib PR 72
      M 64 Never 1 AC/SQ IV NK 2nd/erlotinib PR 108+
      M 70 Ex 1 SQ IV NK 2nd/erlotinib SD 102+
      W 50 Never 1 AC IV Del 19 1st/gefitinib PR 66

      *Del 19 and T790M

      Conclusion

      The treatment was safe and effective in our group of patients with advanced NSCLC treated with gefitinib or erlotinib for over 5 years. The NGS analysis of the available samples will be done after approval of the submitted Protocol by the Ethics Committee.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.